IMTX vs MLTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IMTX · Immatics$5.77 ▼ 3.03%
MLTX · MoonLake Immunotherapeutics$11.07 ▲ 0.36%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IMTX -45.6%
- MLTX -15.8%
Head to head
| Metric | IMTX | MLTX |
|---|---|---|
| Price | $5.77 | $11.07 |
| Change today | ▼ 3.03% | ▲ 0.36% |
| Market cap | $878.58M | $942.13M |
| Return, 3 months | -33.6% | -28.0% |
| Return, year to date | -45.0% | -16.0% |
| Return, 1 year | -43.4% | -12.6% |
| P/E (TTM) | – | – |
| P/B | 1.8 | 2.5 |
| P/E percentile vs own 5y | 77th | 87th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +33.5% | – |
| Net profit growth (YoY) | -50.4% | -12.5% |
| Gross margin | – | – |
| Operating margin | -577.1% | – |
| Net margin | -526.6% | – |
| Return on equity | -53.5% | -81.6% |
| Analyst target vs. price | +173.1% | +221.3% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 29 | 44 |
| 30-day volatility | 56.4% | 80.9% |
| Max drawdown, 1 year | -51.4% | -56.9% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MLTX is the largest of the group by market value.
- MLTX has returned the most over the past year.
- IMTX has been the calmest stock over the last 30 days.